<DOC>
	<DOCNO>NCT00216398</DOCNO>
	<brief_summary>The purpose study ass efficacy , safety patient acceptability Somatuline Autogel patient acromegaly previously treat octreotide LAR .</brief_summary>
	<brief_title>Lanreotide Autogel Patients With Acromegaly Previously Treated With Octreotide LAR</brief_title>
	<detailed_description />
	<mesh_term>Acromegaly</mesh_term>
	<mesh_term>Lanreotide</mesh_term>
	<mesh_term>Angiopeptin</mesh_term>
	<mesh_term>Octreotide</mesh_term>
	<mesh_term>Somatostatin</mesh_term>
	<criteria>Clinical diagnosis acromegaly The patient must test Week 4 ( 4 week prior Baseline visit ) show GH level &lt; 10 mU/L . The patient must treat stable dose octreotide LAR least four month prior study entry Life expectancy least 2 year Adenectomy within past 6 month , likely study period Radiotherapy acromegalic disease within 1 year , likely study period Unstable concomitant dopamine agonist therapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2007</verification_date>
	<keyword>acromegaly</keyword>
	<keyword>growth hormone</keyword>
</DOC>